Lit Matters #2: 2025 GOLD Report updates

COPD exacerbation severity can now be graded at first contact rather than inferred from the treatment you end up giving. The 2025 GOLD update also pushes emergency clinicians to think beyond “just COPD,” with tighter steroid and antibiotic courses, earlier NIV for respiratory failure, and more attention to cardiovascular overlap.

COPD Exacerbation Assessment and Management

• Rome severity proposal: The Rome proposal classifies COPD exacerbations at the bedside using dyspnea burden, vital signs, oxygen saturation, and CRP, giving ED teams a real-time triage framework. We walk through the practical cut points in the episode.
• Severe exacerbation definition: Severe exacerbation means the clinical criteria are met plus acute hypercapnic respiratory failure with acidosis, anchoring ICU-level concern to the blood gas rather than to how much treatment has been given.
• Short steroid course: Prednisone 40 mg daily for 5 days remains the headline systemic steroid regimen, with better lung function and faster recovery but no proven benefit from extending the course.
• Antibiotic trigger symptoms: Antibiotics belong when Anthonisen features are present, especially increased sputum purulence paired with more dyspnea or sputum volume, and the recommended course is just 5 days.
• Avoid methylxanthines: Theophylline and other methylxanthines are explicitly not recommended in acute exacerbations because the adverse-effect burden outweighs any marginal bronchodilator benefit.
• NIV before intubation: Noninvasive ventilation is first-line for COPD patients with acute respiratory failure, especially respiratory acidosis, because it lowers intubation rates, shortens length of stay, and improves survival.

Cardiovascular Overlap and Prevention

• Broader dyspnea differential: Worsening respiratory symptoms are not specific for COPD; pneumonia, acute heart failure, and pulmonary embolism stay near the top of the ED differential when the story does not quite fit.
• COPD cardiovascular syndemic: GOLD frames COPD and cardiovascular disease as a syndemic, with shared risk factors and bidirectional worsening that raises concern for MI and arrhythmias during and after exacerbations.
• Cardiac biomarker role: Troponin and BNP may help during a presumed COPD exacerbation when ischemia or heart failure is in the differential or the response to standard therapy is unexpectedly poor.
• Discharge vaccine updates: Exacerbation prevention now includes RSV vaccination for older adults and patients with chronic heart or lung disease, alongside annual influenza, pneumococcal PCV20 or PCV21, and Tdap.